223 related articles for article (PubMed ID: 14691123)
1. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
2. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
3. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
[TBL] [Abstract][Full Text] [Related]
4. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
6. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
7. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Opin Biol Ther; 2002 Mar; 2(3):335-42. PubMed ID: 11890872
[TBL] [Abstract][Full Text] [Related]
8. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
9. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
10. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
13. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
14. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
Berd D
Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
16. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
19. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
20. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma.
Peng B; Liang L; Chen Z; He Q; Kuang M; Zhou F; Lu M; Huang J
Hepatogastroenterology; 2006; 53(69):409-14. PubMed ID: 16795983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
